Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S.
Tempus AI (NASDAQ: TEM) has announced the formation of its Advisory Board, comprising distinguished physicians from leading medical institutions across the United States. The board will provide strategic guidance on research, product development, and clinical utility of Tempus's AI-enabled platform for precision medicine.
Led by Dr. Ezra Cohen, Chief Medical Officer of Oncology at Tempus, the advisory board includes 13 renowned medical professionals specializing in various oncology fields. Notable members include directors and professors from prestigious institutions such as Ohio State University Medical Center, UCLA, MD Anderson Cancer Center, Mayo Clinic, and Vanderbilt-Ingram Cancer Center.
The advisory board's primary focus will be maintaining high standards and ensuring the company's strategy remains grounded in expert knowledge, supporting Tempus's mission of advancing precision medicine and patient care through AI technology.
Tempus AI (NASDAQ: TEM) ha annunciato la costituzione del suo Consiglio Consultivo, composto da medici di spicco provenienti da importanti istituzioni mediche degli Stati Uniti. Il consiglio fornirà orientamenti strategici su ricerca, sviluppo prodotto e utilità clinica della piattaforma di medicina di precisione abilitata all'IA di Tempus.
Guidato dal Dott. Ezra Cohen, Chief Medical Officer di Oncologia presso Tempus, il consiglio consultivo include 13 rinomati professionisti medici specializzati in diversi ambiti dell'oncologia. Tra i membri di rilievo figurano direttori e professori di istituzioni prestigiose come Ohio State University Medical Center, UCLA, MD Anderson Cancer Center, Mayo Clinic e Vanderbilt-Ingram Cancer Center.
Il focus principale del consiglio sarà mantenere elevati standard e garantire che la strategia aziendale rimanga radicata in conoscenze esperte, supportando la missione di Tempus di far progredire la medicina di precisione e la cura del paziente tramite la tecnologia IA.
Tempus AI (NASDAQ: TEM) ha anunciado la formación de su Consejo Asesor, compuesto por destacados médicos de instituciones médicas líderes en Estados Unidos. El consejo brindará orientación estratégica sobre investigación, desarrollo de productos y utilidad clínica de la plataforma de medicina de precisión habilitada con IA de Tempus.
Dirigido por el Dr. Ezra Cohen, Director Médico de Oncología en Tempus, el consejo asesor incluye a 13 reconocidos profesionales médicos especializados en diversas áreas de oncología. Entre sus miembros destacados se encuentran directores y profesores de instituciones prestigiosas como Ohio State University Medical Center, UCLA, MD Anderson Cancer Center, Mayo Clinic y Vanderbilt-Ingram Cancer Center.
El enfoque principal del consejo asesor será mantener altos estándares y asegurar que la estrategia de la empresa se base en conocimientos expertos, apoyando la misión de Tempus de avanzar en la medicina de precisión y el cuidado del paciente a través de la tecnología de IA.
Tempus AI (NASDAQ: TEM)는 미국 내 주요 의료 기관의 저명한 의사들로 구성된 자문위원회를 구성했다고 발표했습니다. 이 위원회는 Tempus의 AI 기반 정밀 의학 플랫폼에 대한 연구, 제품 개발 및 임상 활용에 관한 전략적 지침을 제공할 예정입니다.
에즈라 코헨 박사(Tempus 종양학 최고 의료 책임자)가 이끄는 자문위원회에는 다양한 종양학 분야의 13명의 저명한 의료 전문가들이 포함되어 있습니다. 주요 위원으로는 오하이오 주립대학교 의료센터, UCLA, MD 앤더슨 암센터, 메이요클리닉, 밴더빌트-잉그램 암센터 등 명성 높은 기관의 이사 및 교수들이 있습니다.
자문위원회의 주요 목표는 높은 수준을 유지하고 회사의 전략이 전문가의 지식에 기반하도록 보장하는 것이며, AI 기술을 통한 정밀 의학과 환자 치료 발전이라는 Tempus의 사명을 지원하는 것입니다.
Tempus AI (NASDAQ : TEM) a annoncé la formation de son Conseil consultatif, composé de médecins éminents issus d'institutions médicales de premier plan aux États-Unis. Ce conseil fournira des orientations stratégiques en matière de recherche, de développement de produits et d'utilité clinique de la plateforme de médecine de précision assistée par IA de Tempus.
Dirigé par le Dr Ezra Cohen, directeur médical en oncologie chez Tempus, le conseil consultatif regroupe 13 professionnels médicaux réputés spécialisés dans divers domaines de l’oncologie. Parmi les membres notables figurent des directeurs et professeurs d’institutions prestigieuses telles que l’Ohio State University Medical Center, UCLA, le MD Anderson Cancer Center, la Mayo Clinic et le Vanderbilt-Ingram Cancer Center.
La mission principale du conseil consultatif sera de maintenir des normes élevées et de veiller à ce que la stratégie de l’entreprise reste ancrée dans un savoir-expert, soutenant ainsi la mission de Tempus qui vise à faire progresser la médecine de précision et les soins aux patients grâce à la technologie IA.
Tempus AI (NASDAQ: TEM) hat die Gründung seines Beirats bekanntgegeben, der aus angesehenen Ärzten führender medizinischer Einrichtungen in den Vereinigten Staaten besteht. Der Beirat wird strategische Beratung zu Forschung, Produktentwicklung und klinischem Nutzen der KI-gestützten Plattform von Tempus für Präzisionsmedizin bieten.
Unter der Leitung von Dr. Ezra Cohen, Chief Medical Officer für Onkologie bei Tempus, umfasst der Beirat 13 renommierte Mediziner, die sich auf verschiedene Bereiche der Onkologie spezialisiert haben. Bedeutende Mitglieder sind Direktoren und Professoren von renommierten Institutionen wie dem Ohio State University Medical Center, UCLA, MD Anderson Cancer Center, Mayo Clinic und Vanderbilt-Ingram Cancer Center.
Der Schwerpunkt des Beirats liegt darauf, hohe Standards aufrechtzuerhalten und sicherzustellen, dass die Unternehmensstrategie auf fachkundigem Wissen basiert, um die Mission von Tempus zu unterstützen, die Präzisionsmedizin und die Patientenversorgung durch KI-Technologie voranzutreiben.
- Strategic enhancement of clinical expertise through formation of high-profile medical advisory board
- Access to guidance from 13 renowned medical professionals from prestigious institutions
- Strengthened positioning in precision medicine and AI healthcare technology
- None.
“Since the beginning, our belief has been that clinical need and strong science must drive our work,” said Ezra Cohen, MD, Chief Medical Officer, Oncology at Tempus. “In that vein, we have formed the Tempus Advisory Board which solidifies this intent and overall mission. We are thrilled to gather this group of internationally renowned, experienced, and passionate physician leaders to support and guide our scientific and medical direction across the company, and we look forward to expanding the board as we continue to grow and evolve.”
This group features the following advisors:
- David Carbone, MD, PhD: Dr. Carbone is a Professor of Medical Oncology, Director of the James Thoracic Oncology Center at the Ohio State University Medical Center.
- Babar Bashir, MD, MS, FACP: Dr. Bashir is an Associate Professor with a primary appointment in the Department of Medical Oncology, Division of Solid Tumors, and a secondary appointment in the Department of Pharmacology, Physiology, & Cancer Biology at Thomas Jefferson University.
- Amy Cummings, MD, PhD: Dr. Cummings is an assistant professor in the division of hematology/oncology at the University of California Los Angeles.
- Tapan M. Kadia, MD: Dr. Kadia is a Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center and serves as Co-leader of the sections of AML and developmental therapeutics.
-
Marc R. Matrana, MD: Dr. Matrana is an Endowed Professor and System Director of Precision Medicine at Ochsner MD Anderson Cancer Center. He also holds a Full Professorship at the University of
Queensland . His medical oncology practice focuses on cancers of the genitourinary tract. - Robert McWilliams, MD, MSc, MSHA: Dr. McWilliams is a consultant and Professor of Oncology at Mayo Clinic as well as Deputy Director of the Cancer Practice at the Mayo Clinic Comprehensive Cancer Center.
-
Tara Mitchell, MD: Dr. Mitchell is the Section Chief, Melanoma and Sarcoma, Hematology Oncology and Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of
Pennsylvania . - Nicholas Mitsiades, MD, PhD: Dr. Mitsiades is the Albert Holmes Rowe Chair of Genetics Ill Professor of Medicine and Associate Director for Translational Research at the UC Davis Comprehensive Cancer Center.
- Ben Park, MD, PhD: Dr. Park is the Director of the Vanderbilt-Ingram Cancer Center. Dr. Park is also a Professor of Medicine in the Department of Medicine's Division of Hematology and Oncology.
- B. J. Rimel, MD: Dr. Rimel is an Associate Professor of Obstetrics & Gynecology at Cedars-Sinai and the Medical Director of Cancer Clinical Trials Office at Cedars-Sinai Cancer.
- Mothaffar Rimawi, MD: Dr. Rimawi is the Executive Medical Director of the Dan L Duncan Comprehensive Cancer Center.
- Assuntina G. Sacco, MD: Dr. Sacco is a Professor of Internal Medicine, Division of Hematology-Oncology, and Co-Director of the Hanna and Mark Gleiberman Head and Neck Center of Excellence at UC San Diego Health Moores Cancer Center.
- Alexander Spira, MD, PhD: Dr. Spira is the Co-Director of the Virginia Cancer Specialists Research Institute, CEO and Director of NEXT Oncology Virginia, Chair of the Research Advisory Board of USOncology, and Clinical Assistant Professor at Johns Hopkins.
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the potential impact of biological modeling solutions in therapeutic research and discovery, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250418999150/en/
Erin Carron
media@tempus.com
Source: Tempus AI, Inc.
FAQ
What is the purpose of Tempus AI's (TEM) new Advisory Board?
How many medical professionals are on the Tempus (TEM) Advisory Board?
Who leads the Tempus (TEM) Advisory Board initiative?
Which major medical institutions are represented on the Tempus (TEM) Advisory Board?
